What non‑sedating (second‑generation) antihistamines are recommended and what are the appropriate dosing regimens for adults and children, including adjustments for renal or hepatic impairment?

Non-Sedative Antihistamines: Recommended Agents and Dosing

Second-generation antihistamines are generally preferred over first-generation antihistamines, with fexofenadine, loratadine, and desloratadine being the most truly non-sedating options at recommended doses. 1

Recommended Second-Generation Antihistamines

Truly Non-Sedating Agents (First Choice)

The following agents cause no sedation at recommended doses and maintain this profile even at higher doses:

• Fexofenadine: The gold standard for non-sedation; shows no sedative properties even at doses exceeding FDA-approved levels 1, 2
• Loratadine: Non-sedating at recommended doses (may cause sedation only when exceeding recommended doses) 1
• Desloratadine: Non-sedating at recommended doses (may cause sedation only when exceeding recommended doses) 1

Potentially Mildly Sedating Agents (Second Choice)

• Cetirizine: May cause mild sedation at recommended doses (13.7% vs 6.3% placebo in patients ≥12 years), though typically milder than first-generation agents 1

Standard Dosing Regimens

Adults

• Fexofenadine: Standard dose (typically 60-180 mg once daily)
• Loratadine: Standard dose (typically 10 mg once daily)
• Desloratadine: Standard dose (typically 5 mg once daily)
• Cetirizine: 10 mg once daily (may cause mild drowsiness)

Dose Escalation Strategy

For inadequate symptom control, increase second-generation antihistamine doses up to 4-fold the standard dose before adding other therapies 3, 4. This approach is supported by recent guidelines and has been shown to enhance symptom control without compromising tolerability 5.

Step-up approach:

1. Start with standard-dose second-generation antihistamine
2. After 2-4 weeks (or earlier if symptoms intolerable): Increase dose up to 4 times standard
3. Maintain increased dose for at least 3 consecutive months of complete control before considering step-down
4. When stepping down, reduce by no more than 1 tablet per month 3

Adjustments for Organ Impairment

Renal Impairment 6

Cetirizine, levocetirizine:

• Moderate impairment (CrCl 10-20 mL/min): Reduce dose by 50%
• Severe impairment (CrCl <10 mL/min): Avoid

Loratadine and desloratadine:

• Use with caution in severe renal impairment

Fexofenadine:

• Generally well-tolerated; primarily hepatically metabolized with minor renal excretion 7

Hepatic Impairment 6

Most second-generation antihistamines:

• No dose adjustment typically required for mild-to-moderate hepatic impairment
• Limited data available; use with caution in severe hepatic disease

Cetirizine:

• Minimal hepatic metabolism; primarily renally excreted, making it relatively safer in hepatic impairment 7, 8

Special Populations

Pediatric Patients

• Antihistamine half-lives are generally shorter in children than adults 7
• Patients with low body mass may reach elevated dosage levels (mg/kg basis) with standard age-based dosing, potentially causing drowsiness 1
• Adjust doses based on weight rather than age alone when possible

Elderly Patients

• Exercise particular caution: Older adults are more sensitive to psychomotor impairment and at increased risk for falls, fractures, and subdural hematomas 1
• Terfenadine, loratadine, and cetirizine may have longer half-lives in elderly adults 7
• Prefer fexofenadine, loratadine, or desloratadine due to superior safety profile and lack of anticholinergic effects

Pregnancy and Lactation 6

• Best practice: Avoid all antihistamines during pregnancy, especially first trimester
• If treatment necessary: Loratadine and cetirizine are FDA Pregnancy Category B
• Chlorphenamine (first-generation) often chosen in UK due to long safety record, but carries sedation risk
• Never administer to nursing mothers

Key Clinical Pearls

Performance impairment can exist without subjective awareness of drowsiness 1. Patients may deny sedation while still experiencing measurable cognitive and psychomotor deficits.

Avoid AM/PM split dosing (second-generation in morning, first-generation at night) as this strategy does not prevent daytime drowsiness due to prolonged half-lives and persistent end-organ effects 1.

No single second-generation antihistamine has been conclusively found superior in overall response rates 1, making the choice primarily dependent on sedation profile and patient-specific factors.

Cardiovascular safety is excellent for loratadine, cetirizine, and fexofenadine across all studied populations, including drug-interaction and elevated-dose studies 9, 5.